APVO Insider Grant: 17,300 RSUs Awarded to EVP/COO, One‑Year Vest

Rhea-AI Filing Summary

Jeffrey G. Lamothe, identified as EVP and COO of Aptevo Therapeutics (APVO), was granted 17,300 restricted stock units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock, the grant is recorded as an acquisition of derivative securities at a reported price of $0.00, and the filing shows 17,300 shares of direct beneficial ownership following the transaction.

The RSUs vest in full on the first anniversary of the grant date, so conversion into common shares is contingent on that vesting event. The Form 4 discloses this equity award and the resulting change in the reporting person's beneficial ownership for SEC transparency.

Insights

Corporate Governance Specialist

TL;DR A time‑based RSU grant of 17,300 shares was reported as direct beneficial ownership; vesting is one year.

The filing documents a standard executive equity award: 17,300 RSUs that convert one‑for‑one into common stock and vest in full after one year. The award is recorded at a $0.00 price and is reported as direct beneficial ownership upon grant. From a governance disclosure perspective, the Form 4 provides the required transparency about the change in insider holdings and the vesting schedule; it does not disclose any performance conditions or alternative vesting terms.

Compensation Analyst

TL;DR The grant increases the executive's potential shareholding by 17,300 RSUs with a one‑year time vest.

The instrument is a Restricted Stock Unit converting one‑for‑one into common stock, with all 17,300 units vesting on the first anniversary of the grant date. The reported $0.00 price indicates no cash payment for the award at grant. The filing does not provide valuation, grant rationale, or details on whether the grant is part of a broader compensation plan, so assessment of materiality or cost to the company cannot be determined from this document alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lamothe Jeffrey G.

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, COO

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2025		A		17,300		(2)	(2)	Common Stock	17,300	$0	17,300	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. The RSUs vest in full on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did APVO insider Jeffrey Lamothe acquire?

The Form 4 reports an acquisition of 17,300 Restricted Stock Units (RSUs) that convert one‑for‑one into common stock.

When do the RSUs vest for APVO (APVO) insider?

The RSUs vest in full on the first anniversary of the grant date, as stated in the filing.

What ownership change was reported for APVO (APVO)?

The filing shows 17,300 shares of direct beneficial ownership following the reported RSU acquisition.

Was there any cash paid for the RSUs in the Form 4?

The RSUs are reported with a $0.00 price, indicating no cash consideration reported for the award.

Is the transaction tied to a performance condition or 10b5‑1 plan?

The filing states that the RSUs convert one‑for‑one and vest on a time schedule; it does not disclose any performance conditions, and it does not indicate that the transaction was executed under a 10b5‑1 trading plan.